IMPORTANCE OF PROBIOTICS IN THE PREVENTION AND TREATMENT OF COVID-19

Majid Eslami1,2, Anna Abdolshahi1, Alireza Emadi1, Bahman Yousefi1*

Address(es): Bahman Yousefi
1 Food Safety Research Center (salt), Semnan University of Medical Sciences, Semnan, Iran.
2 Department of Bacteriology and Virology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
3 Cancer Research Center, Semnan University of Medical Sciences, Semnan, Iran.
*Corresponding author: yousefi.bahman@semums.ac.ir

ARTICLE INFO
Received 9. 3. 2021
Revised 27. 9. 2022
Accepted 20. 10. 2022
Published 1. 12. 2022

ABSTRACT
The novel severe acute respiratory syndrome COVID-19 outbreak is brought on by the SARS-CoV-2 coronavirus. Taking into account the criticism that SARS-CoV-2 has received on a global scale, efficient preventive actions and treatment for COVID-19 would be an urgent need. New strategies were developed based on immune responses. The immunomodulating properties of a few bioactive substances, minerals, and micronutrients have led to recommendations. Probiotics' therapeutic uses in COVID-19 patients were looked into in this review. A decline in the amount of various probiotic species, including Bifidobacterium and Lactobacillus, was observed in some COVID-19 patients, which may be indicative of a compromised immune system. The use of probiotics has been predominantly explored for the inhibition and management handling of gastrointestinal disorders, but other potential properties of these microorganisms have been considered for nutritional effects, inflammatory diseases, Helicobacter pylori infections, allergic diseases, and anti-tumor properties. Some investigations have revealed that these probiotics stimulate and modify innate immune responses through multiple membrane molecules that transfer signaling massages with the epithelial cells of the gut. In addition to the gut microbiota, which has been widely studied, the physiopathology of numerous respiratory illnesses is known to depend on the lung microbiota. Through microaspiration and inhalation, which bacteria, molds, and viruses can create, the healthy lung acquired its unique microbiota. Probiotic strains might be used to influence these microbiotas, contributing novel views in the managing of respiratory diseases. Returning gut microbiota has been revealed to recover resistance to virus or pathogenic invades moreover at the respiratory mucosal stages.

Keywords: COVID-19, Probiotics, Microbiota, Coronavirus, Immunomodulation

INTRODUCTION
A novel coronavirus from the Coronaviridae family is the cause of the 2019 coronavirus disease (COVID-19). Two of the four coronavirus genera α- and β-CoV can infect mammals (Novel 2020). According to reports, the Middle East Respiratory Disease (MERS) outbreak was historically significant and had high mortality rates (Vannabouthong, Devji et al. 2020). Currently, a new form of β-CoV, specifically SARS-CoV-2 (called 2019 novel coronavirus), causes a global pandemic with a high mortality rate. There are no certain medications or vaccines to treat this serious communicable disease (Li, Liu et al. 2020). Despite COVID-19 endangering public health, it is acknowledged as an international emergency (Guo, Cao et al. 2020, He, Ren et al. 2020). Numerous reported pneumonia cases from Wuhan (China) are thought to be the first source of new coronavirus dissemination (Andersen, Rambaut et al. 2020). However, many cases with no traveling history to Wuhan confirmed the human-to-human transmission of COVID-19 (Chen, Yuan et al. 2020). The pathogenesis of SARS-CoV-2 was initiated after the entrance to human cells by genome replication. The ACE2 is proposed as a cell receptor of this virus that manages and regulates the cross-species, and the surface S-glycoproteins of coronavirus are responsible for attaching to ACE2 receptors on human cells (Guo, Cao et al. 2020). To date, the possible transmission route of SARS-CoV-2 included respiratory droplets, close contact, mucous membranes of eyes, mouth or nose, and aerosol also foods (Zhu, Zhang et al., Lu, Liu et al. 2020). Furthermore, many different clinical presentations were reported in patients from moderate to high, such as fever, dry cough, hard breathing, pneumonia, and respiratory infections (Jamshaid, Zahid et al. 2020). Along with various treatments, strategies were assisted in this regard. Person-to-person transmission of the disease has been proven, although different countries have taken many control measures, it should be noted that travel to other areas should be avoided. Besides, many cases may be asymptomatic. Therefore, it is difficult to predict the time of epidemic peak and it will be more difficult to diagnose cases (Peeri, Shrestha et al. 2020).

CURRENT TREATMENT STRATEGIES
Considering the global criticism due to SARS-CoV-2, the implementation of efficient preventive actions and treatment for COVID-19 would be an urgent need (Tang, Liu et al. 2020). Given the varied epidemiological features of SARS-CoV-2, the interruption of the spread chain by current prevention and control programs has not been accomplished. Generally, the primary proposed treatment has been included supportive treatments, anti-viral therapy, cellular therapy, immunotherapy, and Chinese medicine (Li, Liu et al. 2020). The less evidence in therapeutic drugs for controlling the distribution and transmission of virus conducted the researchers to search about other potential ways to combat COVID-19. Also, ineffective anti-viral therapy approaches caused symptomatic and respiratory support to be the focal point of current treatment. Antiviral, antibiotic, anti-parasitic, and new small molecule anti-COVID-19 drugs-blocking cellular entry were among pathogen-targeting techniques that have been shown to be successful against SARS-CoV-2. The design based on host-targeting has been attempted as immunity modifiers such as monoclonal antibodies and interferon-α and corticosteroids that are recommended for COVID-19 treatment (Jamshaid, Zahid et al. 2020). Recent symptomatic treatment approaches varied depending on the severity of the infection, ARDS and septic shock caused by COVID-19, antithrombotic medication, and plasma therapy (Gandhi, Yokoe et al. 2020, Khan, Ali et al. 2020, Lu and Shi 2020). New strategies were developed based on immune responses. Some bioactive compounds, minerals, micronutrients have been recommended due to their immunomodulation effects (He, Ren et al. 2020). One of the most important treatments today is the use of various vaccines, including Live Attenuated Vaccines (LAVs) and Inactivated vaccines (IVs), Viral vectors, Nanotechnology approaches in vaccine, Nucleic acid-based vaccine (DNA and RNA vaccines), Subunit vaccine and Peptide-based vaccines (Umakanthan, Chattu et al. 2021). Probiotic use in promoting the COVID-19 state has received increased attention in this area (Al-Tawfiq and Memish 2020). Many frameworks have documented the mechanism of probiotic intervention as COVID-19 treatment.
PROBIOTICS’ IMPACT ON HEALTH AND DISEASE

According to WHO, FAO, and ISAPP, probiotics are live bacteria that improve the health of the host when given in sufficient amounts (Hill, Guarner et al. 2014). The use has been considered ever since long, especially in the manipulation of gut microbiota (Eslami, Yousefi et al. 2019). Probiotic use has mostly been investigated for the prevention and treatment of gastrointestinal ailments. Still, other potential properties of these microorganisms have been considered for nutritional effects, inflammatory diseases, Helicobacter pylori infections, allergic diseases, and anti-tumoral properties (Adibollahi, Tabatabaie Yazdi et al. 2016, Ghaseemian, Eslami et al. 2018, Adibollahi, Marvdashi et al. 2019, Eslami, Yousefi et al. 2019, Yousefi, Eslami et al. 2019). In cases of antibiotic-associated diarrhea, colitis, pethacaris, and irritable bowel syndrome, the effects of probiotics alone or in combination have been studied (Verna and Lucaok 2010). The most available species of probiotics are Lactobacillus, Bifidobacterium, and butyrates, used in food and dairy products and supplements. Prebiotics selectively used by host microbes and beneficial to health (Lebaka, Wee et al. 2018). Most prebiotics are carbohydrate-based and have also demonstrated a variety of health benefits, including the ability to limit the growth of pathogens and immune system modulation (Sanders, Merenstein et al. 2019). Prebiotics are indigestible to absorption and digestion. Several molecules can perform as short-chain fatty acids (SCFA), peptidoglycans, and polysaccharides. The regulatory mechanism of the immune system is affected by probiotics. Also, the effective functions of probiotics in treating several diseases caused by viruses are well documented (Sanders, Merenstein et al. 2019).

PROBIOTIC EFFECTS ON IMMUNE RESPONSES

Mucus, the movement of the cilia, and secretory IgA in the respiratory tract secretion are the primary mechanisms by which the host achieves protection. Dendritic cells (DC) are persuaded by viral infection to initiate a series of immunological responses, which are followed by the activation of CD4+CD8+ cells and an improvement in specific T and B cell intermediated immunity (Madsen 2006). Microorganisms form a diverse and rich environment on the skin and mucosal surfaces. The correlation between gut microbiota and overall health has been confirmed. Gut microbiota is one of the greatest active sites of the human immune system (Sanders, Merenstein et al. 2019). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017).

CLINICAL EVIDENCE OF PROBIOTIC IMMUNOMODULATION

Local and systemic immunological impacts are linked to interactions between dendritic cells (DC) are persuaded by viral infection to initiate a series of immunological responses, which are followed by the activation of CD4+CD8+ cells and an improvement in specific T and B cell intermediated immunity (Madsen 2006). Microorganisms form a diverse and rich environment on the skin and mucosal surfaces. The correlation between gut microbiota and overall health has been confirmed. Gut microbiota is one of the greatest active sites of the human immune system (Sanders, Merenstein et al. 2019). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017).

CLINICAL EVIDENCE OF PROBIOTIC IMMUNOMODULATION

Local and systemic immunological impacts are linked to interactions between dendritic cells (DC) are persuaded by viral infection to initiate a series of immunological responses, which are followed by the activation of CD4+CD8+ cells and an improvement in specific T and B cell intermediated immunity (Madsen 2006). Microorganisms form a diverse and rich environment on the skin and mucosal surfaces. The correlation between gut microbiota and overall health has been confirmed. Gut microbiota is one of the greatest active sites of the human immune system (Sanders, Merenstein et al. 2019). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017). Diet can alter the gut microbiome, which uses nutrients from eating foods, discharges harmful or helpful metabolites, and regulating the immune system. The intestinal mucosal surface is a significant location of the entrance of pathogens through the mucosa and into the microorganisms playing a vital role in modifying the mucosal immune system (Milani, Duranti et al. 2017).
prostaglandin (Liu, Sheng et al. 2020). *L. plantarum* strains differed physiologically in that they produced acetic acid, oligosaccharides, exopolysaccharides, and tolerated gastrointestinal transit. They also synthesized conjugated linoleic acid (CLA) (Darban, Malek et al. 2021). Probiotics' anti-inflammatory benefits have been researched in recent studies. Weissella cibaria (JW15) inhibited lipopolysaccharide (LPS)-induced NO and PGE2 production by decreasing the expression of iNOS and cyclooxygenase-2 (COX-2). Additionally, it reduced the production of pro-inflammatory cytokines (Ulisse, Gionchetti et al. 2001).

**PROBIOTICS: CONTROL AND TREATMENT OF VIRAL INFECTIONS**

Patients with a suppressed immune system come across dysbiosis conations in the gut microbiota, resulting in the digestive tract’s harmful bacteria. The most severe and difficult-to-treat infections are those brought on by gut bacteria, and they frequently present a threat to life. Treatments with probiotics have been demonstrated to diminish upper or lower respiratory tract infections by improving immune response and combat viral infections (Round and Mazmanian 2009). Oral administration of various strains of *Lactobacillus* and *Bifidobacterium* have revealed suppression of infection indications alongside viral infections (Red and Mazmanian 2009). Probiotics act as modulators of the intestinal flora and promote gut balance and play a role in interferon production as an anti-viral factor (Sundararaman, Ray et al. 2020).

A few of the fundamental mechanisms behind probiotic effectiveness against viruses include host immune system modification, direct probiotic cell contact with the suggested viruses, and the creation of antiviral metabolites. There are many possibilities, ranging from altering the host microbiota to communicating with eukaryotic epithelial cells (Ibrahim 2015). Oral administration of Lactic acid bacteria and their products attend as anti-viral mediators. They are recognized as conferring health aids and also immunomodulatory, anti-tumor, competitive inhibition of pathogens (antibiofilm), and antioxidant properties (Zhang, Yang et al. 2018).

As a probiotic defense against the pneumonia virus, *L. plantarum* or *L. reuteri* decreased granulocyte chemotaxis and release of numerous pro-inflammatory cytokines, and condensed virus recovery through TLR independent pathway. In the other clinical trial study, *L. plantarum* and *L. paracasei* in good subjects decreased the threat of obtaining common cold infections and pharyngeal indications (Shinde 2019). Animal experiments verified probiotic’s roles in reducing virus load tiers and escalating Th cells in the lung and caused diminished virus replication. Probiotics are designated for their capability to suppress the virus by straight interacting with them and escaping viral particles’ attack to mucosal cells and respiratory tract infections. By stimulating Th1 immune responses in mice, the probiotic strain prevented the generation of antigen-specific IgE. It had a protective effect against influenza A virus infection in vivo, which increased natural killer (NK) cell activity and IgA production in vitro (Kho and Lal 2018).

In older people, probiotics like *L. casei* showed increased antibody responses to influenza virus inoculation and boosted the respiratory tract’s innate immune response. Additionally, fight against various respiratory diseases in children and newborns, as well as the populations most at risk for respiratory infections (Lehtoranta, Pitkäranta et al. 2014).

**PROBIOTIC EFFECTS ON CORONAVIRUS INFECTIONS**

There is increasing indication backing the benefit of probiotics as a preventive method to diminish, period and the need for drugs. A possible approach would be to modify the microbiome using probiotics, enabling inhibition or the treatment of respiratory illnesses like COVID-19. *L. plantarum* produces a variety of metabolites, such as: Gamma-aminobutyric acid (GABA), lactic acid, acetic acid, and plantaricin can all boost protection to viruses (Dhar and Mohanty 2020, Novik and Savich 2020). Receptor recognition is the primary period of host cell infection by the virus and one of the most critical features of the host cell. The binding affinity among SARS-CoV and hACE2 can associate with viral transfection and infection. Computational demonstration and molecular dynamics study validate the anti-viral action of Plantaricin combinations. Several mechanistic methods include blocking the entrance of COVID-19 through binding with RNA-dependent RNA polymerase (RdRp), residual binding domain (RBD) to ACE2. In this work, the Plantaricin family of probiotic metabolites induced target both spikes (S) glycoprotein by impairing RBD and ACE2. This computational method was used to restrict the entry of COVID-19 and prevent the effects of Plantaricin compounds by binding to RdRp, RBD, and ACE2. In this investigation, plantaricin metabolites were identified as a potential novel antiviral treatment option for COVID-19 (Anwar, Altaf et al. 2020).

**Fig 1 The probiotic effects on coronavirus infections**

**BACTERICINS AND GUT MICROBIOTA**

The ability of metabolic products such lactic acid, H2O2, and bacteriocins delivered by LAB to reduce viral load has been studied. Bacteriocins can play a big part in host defense, according to another research. LAB probiotics have been found to create proteinaceous compounds synthesized by ribosomes that have bactericidal effect. These anti-microbial proteins have been shown to effectively combat potential pathogens by influencing the host microbiota and a variety of bodily functions. Maintaining gut homeostasis and biocontrolling harmful macromolecules are two potential uses for bacteriocins (García-Gutiérrez, Mayer et al. 2019).

One of the primary anti-viral tools of probiotics, the inhibition of viral replication, has not yet been documented. Peptide CRL35 was produced by *Enterococcus faecium* by inhibiting the last phases of HSV-1/2 replication. *L. delbrueckii*, a very specific restriction on influenza virus H7N7 and H7N1 replication. This view’s activity is probably more useful than in the inflammatory stages of the illness during the early stages of viral infection, when virus loads are relatively low. These factors support the idea that probiotics may be more beneficial as a preventative measure than the current standard of virus treatment.

**THERAPEUTIC IMPLICATIONS**

The current coronavirus disease outbreak (COVID-19) has sparked a flurry of research into ways to prevent, treat, and lower morbidity and fatality rates. Clinical tests showed the presence of cytokine storm symptoms and a significant amount of pro-inflammatory cytokines. IL-1, TNF, IFN, IL-2, IL-8, interferon-inducible protein 10 (IP-10), and macrophage inflammatory protein 1 (MIP-1) were among the chemokines present. Especially in severe patients may lead to more extended hospitalization and a rise in the mortality rate (Mahooti, Mirti et al. 2020).

Therefore, addressing the urgent need to control the cytokine storm may be helpful in COVID-19 treatment. Several modalities such as anti-microbial peptides, bacteriophages, and probiotics can be considered. According to the studies, probiotics have immunomodulatory effects and could improve the intestinal epithelial barrier features. Additionally, they generate anti-microbial compounds, alter the ratio of pro- to anti-inflammatory cytokines, boost T cell and NK cell activity, and raise levels of systemic and mucosal-specific antibodies in the lungs (Azad, Kalan et al. 2018, Sundararaman, Ray et al. 2020) that may lead to viral clearance and prevention of acute respiratory distress syndrome (ARDS) (Azad, Kalan et al. 2018). Probiotics have been shown to have antiviral action against common respiratory viruses (Nama, Hatako et al. 2010, Luoto, Ruuskanen et al. 2014). When *L. plantarum* 06CC2 was taken orally, more IFN-, TNF-, IL-6, and IL-12 were produced in bronco-alveolar lavage fluid (BALF). Additionally, it has the capacity to control the quantity of neutrophils and macrophages infiltrating the BALF of infected mice (Takeda, Takeshita et al. 2011).

On the other hand, probiotics and their bioactive peptides have an inhibitory impact on the ACE enzymes by blocking their active sites. Molecular dynamics studies demonstrated the anti-viral activity of Plantaricin compounds (metabolic products of *L. plantarum*) by blocking the entry by binding with RdRp, residual binding domain (RBD), and ACE2 (Anwar, Altaf et al. 2020).

Several COVID-19 patients displayed lower levels of various probiotic species, including *Bifidobacterium* and *Lactobacillus* in their intestines, which may be related to weak immune function. Re-normalization of the intestinal flora balance by consuming probiotics may lessen the likelihood of infection and the severity of illness (AKTAŞ and Aslım 2020). According to recent research, the most important probiotics that might be associated to reducing the impact of the COVID-19 pandemic are included *B. longum, B. bifidum, B. breve* *L. plantarum*, *L. casei*, *L. gasseri*, *L. rhamnosus*, *Pediococcus pentosaceus*, and *Leuconostoc mesenteroides* (Baud, Agri et al. 2020, Khalid 2020). The therapeutic effects of probiotics against COVID-19 are not backed by any reliable research. Probiotics' immune-stimulating and nutritional effects, as well as their antiviral abilities against a variety of respiratory viruses, point to probiotics as a supplemental treatment for COVID-19 disease that requires further clinical and laboratory research. Table 1 illustrated human studies that other probiotic strains assisted in the treatment of respiratory infections and effect of probiotics bacteria in respiratory infections shown in Table 2.
| Number of patients/ age | Type of disease | Probiotic strain | Product dose, Treatment Period | Treatment Outcome | Reference |
|------------------------|----------------|-----------------|-------------------------------|-----------------|-----------|
| 70 median age 59 years | COVID-19 | S. thermophilus DSM 2345, L. acidophilus DSM 32241, L. helveticus DSM 32242, L. paracasei DSM 32243, L. plantarum DSM 32244, L. brevis DSM 27961, B. lactis DSM 32246, B. lactis DSM 32247 | IG: received 2,400 billion bacteria each day along with hydroxychloroquine, antibiotics, and tocilizumab (Three equal doses) CG: received tocilizumab, antibiotics, and hydroxychloroquine, either separately or in combination. | -Fever, asthenia, headache, myalgia, and dyspnea all disappeared in the patients within seven days, and this trend became more pronounced starting on the second day of bacteriotherapy in IG. -Reduced likelihood of developing a respiratory failure requiring 8 times more resuscitation support in IG. - Every patient in IG recovered from the COVID-19 sickness, and none required invasive mechanical ventilation or hospitalization to the intensive care unit. | (d’Ettorre, Ceccarelli et al. 2020) |
| 2 male patients/ 76 and 73 years (Case Report) | | | | | |
| 479 healthy adults / 18-67 years | Common cold episodes | L. gasseri PA 168, B. longum SP 07/3, B. bifidum MF 205 (Trigion harmonis™) | IG: 5×10^10 cfu/tablet during two winter/spring seasons, of the spray-dried probiotic bacteria along with vitamins and minerals (at least 3 months). CG: Tablet with vitamin minerals (1 tablet/day) | - Days with fever during an episode and the length of the common cold bouts were shorter in IG (almost 2 days). - A significantly higher enhancement of CD8+CD4+ was observed in IG. | (Ventoulis, Sarroufi et al. 2020) |
| 272 healthy volunteers 18-65 years | Common cold episodes | L. plantarum HEAL 9 (DSM 15312) L. paracasei 87002 (DSM 13434) | IG: 1 g of lyophilized bacteria (1×10^9 cfu each day for 12 weeks) and 1 g of maldextrin CG: 10 g maldextrine | - In IG, there was a considerably lower likelihood of developing one or more episodes of the common cold, as well as a shorter duration of time experiencing symptoms and pharyngeal symptoms. - B lymphocyte proliferation was considerably reduced in IG compared to CG. | (Berggren, Ahrén et al. 2011) |
| 222 healthy elderly participants / ≥70 years | Influenza vaccination | L. casei (Actimel® DN-114 001), S. thermophilus, L. bulgaricus | IG: Actimel® 100 g/bottle CG: a control dairy product that is not fermented 100 g per bottle 200 g each day from two bottles for 13 weeks. | - Following vaccination, there was a rise in the titers of influenza-specific antibodies, which were higher in IG than CG. - Five months following immunization, the intended to treat analysis revealed significant variations in seroconversion between the groups. | (Boge, Réminigy et al. 2009) |
| 50 healthy adult human volunteers / 22-56 years | Influenza vaccination | L. fermentum CECT5716 | IG: daily consumed a capsule containing 1×10^7 cfu of L. fermentum in a matrix of the mix of methylcellulose for 28 days CG: Taken each day a 200 mg methylcellulose tablet. | - The IG had an increase in NK cells, whereas the CG did not (2 weeks after vaccination). - Following IG vaccination, there was a considerable rise in blood levels of total and specific anti-influenza IgM. - Five months after immunization, the incidence of an influenza-like illness was reduced in IG. | (Olivares, Díaz-Ropero et al. 2007) |
| 235 critically ill adult patients who were expected to receive mechanical ventilation for >48 h / 18-80 years | VAP | B. subtilis, E. faecalis | IG: receive a capsule contained active Bacillus subtilis and Enterococcus faecalis at a concentration of 4.5×10^5/0.25 g and 0.5×10^5/0.25 g, respectively, three times per day by nasogastric feeding tube along with conventional prophylactic measures for a period of 14 days. CG: standard preventive strategies alone | - In the IG, the incidence of VAP was substantially lower than in the CG. - In the IG compared to the CG, the mean time to develop VAP was substantially longer. - In comparison to the CG, the IG had a smaller percentage of patients who had acquired stomach colonization of PPMOs. -Probiotic therapy had no positive impact on the frequency of clinically suspected VAP, consumption of antibiotics, time spent on mechanical ventilation, death, or length of hospital stay. | (Zeng, Wang et al. 2016) |
| 100 adult critically ill patients undergoing mechanical ventilation for >48 hours / ≥18 years | VAP | L. casei, L. acidophilus, L. rhamnosus, L. bulgaricus, B. breve, B. longum, S. thermophilus | IG: got a probiotic mixture in the form of 2 capsules (1 capsule every 12 hours) every day for 14 days. 10^10 microorganisms were found inside each capsule. CG: for 14 days, a placebo was given every day. | - VAP was less frequent in IG. - In the IG, the length of the ICU and hospital stays was also shorter. | (Mahmoodpoor, Hamishekhar et al 2019) |
| 1783 schoolchildren / 6-12 years | Influenza infection | L. brevis KB290 (KB290) | In one bottle (80 ml), there are 6 billion cfu and a combination of nutrients (0.6 g protein, <0.3 g fat, 7.6 g carbohydrate, <0.5 g fibre, 8 mg Na, 146 kJ) Group A received no therapy for the second eight-week period after receiving five days per week for that time. The drink was given to Group B during the second period but not the first. | - Reduced the risk of infection. | (Waki, Matsumoto et al. 2014) |
Concluded, the study of probiotics in COVID-19 treatment could decrease the risk of other infections in patients with COVID-19. Also, probiotics were capable of interrupting the synthesis of RNA and DNA in such viral infections. Since the control of cytokine storm may have benefits in clinical studies indicated that probiotics in COVID-19 treatment could decrease the risk of other infections in patients with COVID-19. Also, probiotics were capable of interrupting the synthesis of RNA and DNA in such viral infections. Since the control of cytokine storm may have benefits in COVID-19 treatment, probiotics and other modalities can be noticed regarding the strain and dose.

**THE POSSIBLE SIDE EFFECT OF PROBIOTIC**

Since the COVID-19 global pandemic has an unexpected spread globally, it is hard to place a safe drug/product as fast as the virus is distributing. The possible potential of probiotics as non-pharmacological substances considering their advantages, availability, and posing negligible side effects have been successfully applied in the current phenomenon. However, some reported side effects that experienced in different clinical approaches should be taken into account. Mainly reported side effects were nausea, taste disturbance, and diarrhea (Armuzzi, Cremonini et al. 2001, Çekin, Şahintürk et al. 2017, Batista, Da Silva et al. 2020). During follow-up, some studies observed a considerable decrease in adverse effects. Collectively, the administration of probiotics at the stage and dosage that have been tasted has been advised (Infusino, Marazzato et al. 2020). The FDA also states that the probiotic is a generally recognized as safe (GRAS) for humans organism (Pourhossein and Moravejolahkami 2020). Therefore, it is estimated the low risk associated with probiotic administration. However, an overall control should be done regarding the strain and dose.

**CONCLUSION**

This research clarified the function of probiotics as a safe strategy for alleviating the SARS-COV-2 infection. Probiotics possessed notable effects on immune responses in the host and could promote the reaction toward infection. Besides, clinical studies indicated that probiotics in COVID-19 treatment could decrease the risk of other infections in patients with COVID-19. Also, probiotics were capable of interrupting the synthesis of RNA and DNA in such viral infections. Since the control of cytokine storm may have benefits in COVID-19 treatment, probiotics and other modalities can be noticed regarding their immunomodulatory effects. In addition, probiotics have an inhibitory impact on the ACE enzymes and can block the active sites. It is proved that some strains of probiotic microorganisms produce anti-inflammatory interleukins and anti-body in versus the viruses. According to current knowledge, it is emerging needed to apply practical methods for preventing the COVID-19 infection. Considering how effective probiotics are at preventing viral infections, they can use as an alternative and adjuvant nutritional therapy for the treatment of new coronavirus. More clinical research is required for a comprehensive evaluation of the effects of determining strains of probiotics on COVID-19 infection.

---

**Table 2: Effect of probiotics bacteria in respiratory infections.**

| Property | Diarrhea | Fever | Headache | Myalgia | Dyspepsia | Influenza-like illness | VA | Gastric colonization of PPMOs | Duration of ICU | Risk of infection | CXCL8 response | Inflammation specific antibody | NK cell | IFN-γ |
|----------|----------|-------|----------|---------|----------|------------------------|---|-----------------------------|----------------|-------------------|----------------|---------------------------|----------|-------|
| L. acidophilus | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| L. lactis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| L. paracasei | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| L. plantarum | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| L. rhamnosus | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| B. bifidum | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| B. lactis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| B. longum | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| B. animalis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| E. faecalis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| R. subtilis | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| S. thermophilus | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| L. casei | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |

This table shows the probiotic bacteria used in various respiratory infections and also shows the different effects that these bacteria have caused in these infections as increasing and decreasing.

↓ Decrease, ↑ Increase L: lactobacillus, B: Bifidobacterium, E: Enterococcus, S. thermophilus: Streptococcus thermophilus, B. subtilis: Bacillus subtilis, S. cerevisiae: saccharomyces cerevisiae, NK: natural killer cell. PPMOs: potentially pathogenic microorganisms.
Conflict of interest: In publishing this research, all authors have affirmed that they have no competing interests.

AUTHOR CONTRIBUTIONS
Conceptualization: all authors.
Writing–original draft: all authors.
Writing–review & editing: all authors.
Approval of final manuscript: all authors.

REFERENCES
Abdolshahi, A., L. M. Marvdasthi, B. Salehi, M. Shariﬁ-Rad, S. Ghobakhloo, M. Iriti and J. Shariﬁ-Rad (2019). "Antifungal activities of coating incorporated with Saccharomycetes cerevisiae cell wall mannanoprotein on Aspergillus ﬂavus growth and -α-toxin production in pistachio (Pistacia vera L.)." Journal of Food Safety 39(2): e12608. https://doi.org/10.1111/jfs.12608
Abdolshahi, A., F. Tabatabaee Yazdi, A. A. Shabani, S. A. Mortazavi and A. Mohammadi Nafchi (2016). "Antifungal properties of gelatin-based coating containing mannanoprotein from Saccharomycetes cerevisiae on Aspergillus ﬂavus growth in pistachio." Journal of Mazandaran University of Medical Sciences 26(139): 93-102.

AKTAŞ, B. and B. Aslim (2020). "Gut-lung axis and dysbiosis in COVID-19." Turkish Journal of Biology 44(S1): 1-265.
Al-Tawfiq, J. A. and Z. A. Mernish (2020). "COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies." International Journal of Antimicrobial Agents 55(5): 105968. https://doi.org/10.1016/j.ijantimicag.2020.105968
Amornphimoltham, P., S. P. Yuen, R. A. Star and A. Leelahavanichkul (2019). "The proximal origin of SARS-CoV-2:" Nature medicine 26(4): 450-452. https://doi.org/10.1038/s41591-020-0820-9
Anwar, F., H. N. Altayb, F. A. Al-Abbas, A. L. Al-Malki, M. A. Kamal and V. Kumar (2020). "Antiviral Effects of Probiotic metabolites on COVID-19." Journal of Biomolecular Structure and Dynamics (just-accepted): 1-11. https://doi.org/10.1080/20793911.2020.1775123
Arzu, A., F. Cremonini, F. Bartolozzi, F. Canduci, M. Candelli, V. Ojetti, G. Cammarota, M. A., A. De Lorenzo and P. Pola (2011). "The effect of oral administration of lacticobacilli GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy." Alimentary pharmacology & therapeutics 35(2): 163-169. https://doi.org/10.1111/j.1365-2036.2011.04923.x
Azad, M., A. Kalam, M. Sarker and D. Dan (2018). "Immunomodulatory effects of probiotics on cytokine proﬁles." BioMed Research International 2018. https://doi.org/10.1155/2018/8063647
Baitsa, V. L., C. F. Da Silva, L. C. L. De Jesus, N. Dias Coelho, F. A. L. Barroso, L. M. Tavares, V. A. D. C. Azevedo, P. D. C. Mancha and M. V. Batista, V. L., T. F. Da Silva, L. C. L. De Jesus, N. Dias Coelho and M. V. Batista (2020). "Immunomodulatory effects of probiotics and prebiotics, synbiotics and paraprobiotics as a Therapeutic Alternative for Intestinal Mucositis Running head: Alternative Therapeutics. Probiotics, Prebiotics, Synbiotics & Therapeutics: A Scoping Review." Nutrients 12(3): 820. https://doi.org/10.3390/nu12030820
Bogé, T., M. Rémigy, S. Vaudaine, J. Tanguy, R. Bourdet and X. Sicard and S. Van Der Meeren (2016). "Antifungal properties of gelatin-based coating containing mannanoprotein from Saccharomyces cerevisiae cell wall mannoprotein on Aspergillus flavus growth in pistachio." Current information on the association of Helicobacter pylori with autophagy and implications." Journal of Gastroenterology 52(9): 1023-1033. https://doi.org/10.1007/s00535-018-1426-6
Faner, R., O. Sibila, A. Agusti, E. Bernasconi, J. D. Chalmers, G. B. Huffnagle, C. M. Manchich, P. L. Moinaux, R. Paredes and V. P. Brocal (2017). "The microbiome in respiratory medicine: current challenges and future perspectives." European Respiratory Journal 49(4): 160286. https://doi.org/10.1183/13993003.02886-2016
Gandhi, M., D. S. Yokoe and D. V. Hlavirt (2020). Asymptomatic transmission, the Achilles’ heel of current strategies to control COVID-19, Mass Soc Med 283(22): 2158-2160. https://doi.org/10.22034/MSM.2020.09.20958
García-Gutierrez, E., M. J. Mayer, P. D. Cotter and A. Narbad (2019). "Gut microbiota as a source of novel anti-microbials." Gut microbes 10(1): 1-21. https://doi.org/10.1080/19490976.2018.1455790
Ghaseinian, M. A., E. Smili, M. Shafiee, S. Najafipour and A. Rahabi (2018). "Probiotics and their increasing importance in human health and infection control." Probiotics &amp; Therapeutics 10(1): 153-158. https://doi.org/10.1097/MRM.0000000000000147
Guo, Y.-R., Q.-D. Cao, Z.-S. Hong, Y.-Y. Tan, S.-D. Chen, H.-J. Jin, K.-S. Tan, D.-Y. Wang and Y. Yan (2020). "The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19): overview-an update on the status." Military Medical Research 7(1): 1-10. https://doi.org/10.1186/s40779-020-00240-0
Hansen, A. K., C. H. F. Hansen, L. Krych and D. S. Nielsen (2014). "Impact of the gut microbiota on rodent models of human disease." World Journal of Gastroenterology 20(47): 17772. https://doi.org/10.3748/wjg.v20.i47.17772
Hathaway-Schrader, J. D., H. M. Stein Kamp, M. B. Chavez, N. A. Pouldes, J. E. Kirkpatrick, M. E. Chew, E. Huang, A. V. Alekseyenko, J. J. Aguirre and C. M. Novince (2019). "Antibiotic perturbation of gut microbiota dysregulates oestrogenic cross talk in postpubertal skeletal development." The American journal of physiology-endocrine, Diabetes & metabolism 189(2): 370-390. https://doi.org/10.1152/ajpendo.00187.2017
He, L.-H., L.-F. Ren, J.-F. Li, Y.-N. Wu, X. Li and L. Zhang (2020). "Intestinal flora as a potential strategy to fight SARS-CoV-2 infection." Frontiers in Microbiology 11. https://doi.org/10.3389/fmicb.2020.01388
Hill, C., F. Guarner, G. Reid, G. R. Gibson, D. J. Merenstein, B. Pot, L. Morelli, R. B. Canani, H. J. Flint and S. Salminen (2014). "Expert consensus document: the scope and appropriate use of the term probiotic." The European Society for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic." Nature reviews Gastroenterology & hepatology 11(8): 506. https://doi.org/10.1038/nrgastro.2014.66
Hills, R. D. A. Bontenfret, K. H. Michel, C. A. Black, S. C. Sutton and C. R. Theberge (2019). "Gut microbiome: profound implications for diet and disease." Nutrients 11(7): 1613. https://doi.org/10.3390/nu11071613
Ibrahim, M. D. (2015). "Evolution of probiotics in aquatic world: Potential effects, the current status in Egypt and recent perspectives." Journal of Advanced Research 6(6): 765-791. https://doi.org/10.1016/j.jare.2015.12.004
Infusino, F., M. Marazzato, M. Mancone, F. Fedele, C. M. Mastroianni, P. Severino, G. Ceccarelli, L. Santinelli, E. Cavarretta and A. G. Marullo (2020). "The proximal origin of SARS-CoV-2: a Scoping Review." Nutrients 12(6): 1718. https://doi.org/10.3390/nu12061718
Jamsheid, H., F. Zahid, A. ud Din, A. Zeb, H. G. Choi, G. M. Khan and F. ud Din (2021). "Antimicrobial drug susceptibility testing of SARS-CoV-2 for COVID-19." AAPS PharmSciTech 22(6): 1-14. https://doi.org/10.1007/s12249-020-01756-3
Kayaama, H., R. Okumura and K. Takeda (2020). "Interaction Between the Microbiota, Epithelia, and Immune Cells in the Intestine." Annual Review of Immunology 38: 23–48. https://doi.org/10.1146/annurev-immunol-070119-115104
Khaled, J. M. (2020). “Probiotics, prebiotics, and COVID-19 infection: A review article.” Saudi Journal of Biological Sciences. https://doi.org/10.1016/j.sjbs.2020.11.025

Khan, S., A. Ali, H. Shi, R. Siddique, G. Nabi, J. Hu, T. Wang, M. Dong, W. Zhang and G. Yuan (2020). “COVID: Clinical aspects and therapeutic responses.” Saudi Pharmaceutical Journal 28(8): 1004-1008. https://doi.org/10.1016/j WorsePharm.2020.06.022

Kho, Z. Y. and S. K. Lal (2018). “The human gut microbiome—a potential controller of wellness and disease.” Frontiers in microbiology 9: 1835. https://doi.org/10.3389/fmicb.2018.01835

Kinoshita, T., K. Maniyama, K. Suyama, M. Nishijima, K. Amakatsu, A. Jogamoto, K. Katakami and I. Saito (2019). “The effects of OLL1073R-1 yogurt intake on influenza incidence and immunological markers among women healthcare workers: a randomized controlled trial.” Food & Function 10(12): 8129-8136. https://doi.org/10.1039/c9fd00325a

Lebaka, V. R., Y. F. Wei, V. R. Narala and V. K. Joshi (2018). Development of new probiotic foods—a case study on probiotic juices. Therapeutic, Probiotic, and Unconventional Foods, Elsevier: 55-78.

Lehtoranta, L., A. Pirkkara and R. Korpeila (2014). “Probiotics in respiratory virus infections.” European journal of clinical microbiology and infectious diseases 33(8): 1289-1302. https://doi.org/10.1007/s10096-014-2086-x

Li, H., S.-M. Liu, X.-H. Yu, S.-L. Tang and C.-K. Tang (2020). “Coronavirus disease 2019 (COVID-19): current status and future perspective.” International journal of anti-microbial agents: 105951.

Liu, Y., Y. Sheng, Q. Pan, Y. Xue, L. Yu, F. Tian, J. Zhao, H. Zhang, Q. Zhai and W. Chen (2020). “Identification of the key physiological characteristics of Lactobacillus plantarum strains for ulcerative colitis alleviation.” Food & Function 11(2): 1279-1291. https://doi.org/10.1039/c9fo02935d

Darban, M., Malek, F. Memarian, M. Golian, A. Kiani, A. Esmadi, A. Lavasf, S. Bagheri and B. (2021). “Efficacy of high dose vitamin C, melatonin and zinc in Iranian patients with acute respiratory syndrome due to coronavirus infection: a pilot randomized trial.” J Cell & Mol Anes 6(2): 164-17.

Lu, C.-W., X.-F. Liu and Z.-F. Jia (2020). “2019-nCoV transmission through the ocular surface must be not ignored.” Lancet (London, England) 395(10224): e39. https://doi.org/10.1016/S0140-6736(20)30313-5

Lu, Q. and Y. Shi (2020). “Coronavirus disease (COVID-19) and neonate: What neonatologist need to know.” Journal of medical virology 92(6): 564-567. https://doi.org/10.1002/jmv.25740

Luoto, R., O. Ruskuikian, M. Waris, M. Kalliomaki, S. Salminen and E. Isolauri (2014). “Probiotic and prebiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial.” Journal of Allergy and Clinical Immunology 133(2): 405-413. https://doi.org/10.1016/j.jaci.2013.08.020

Madsen, K. (2006). “Probiotics and the immune response.” Journal of clinical gastroenterology 40(3): 232-234. https://doi.org/10.1097/00004836-200603000-00014

Mahmoodpoor, A., H. Hamashkehr, R. Asghari, R. Abri, K. Shadvar and S. Sanaee (2019). “Effect of a Probiotic Preparation on Ventilator-Associated Pneumonia in Critically Ill Patients Admitted to the Intensive Care Unit: A Prospective Double-Blind Randomized Controlled Trial.” Nutrition in Clinical Practice 34(1): 156-162. https://doi.org/10.1177/0891375818792133

Mahe, M., M. Minge, M. Abdolaliopur and A. Ghaemi (2020). “The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?” Microbial pathogenesis: 104452.

McCarrivie, J. L., Y. Q. Chen, V. D. Cuervas, K. Troha and J. S. Ayres (2020). “Microbiota Metabolites in Health and Disease.” Annual Review of Immunology 38: 147-170. https://doi.org/10.1146/annurev-immune-071219-125715

Milani, C., S. Duranti, F. Bottacini, E. Casey, F. Turroni, J. Mahony, C. Belzer, S. Duranti, C. Belzer and M. Campieri (2001). “Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotics to combat viral infections with emphasis on COVID-19.” Applied microbiology and biotechnology: 1-16. https://doi.org/10.1007/s00253-020-10832-4

Mukaddem, C., T. Devy, S. Ekhbara, Y. Chang, S. A. Phillips, M. Zhu, Z. Chagla, C. Main and M. Bhandari (2020). “Novel coronavirus COVID-19: current evidence and evolving strategies.” The journal of bone and joint surgery. American volume 102(9): 734. https://doi.org/10.2106/jbjs.20.00039

Ventilous, I., T. Sarmouri, P. Amouroudi, P. Mantzana, E. Exidari, G. Gioula and A. Vyzantiadou (2020). “Bloodstream infection by Saccharomyces cerevisiae in 2 COVID-19 patients after receiving supplementation of Saccharomyces in the ICU.” Journal of Fungi 6(3): 98. https://doi.org/10.3390/fungi6030098

Verna, E. C. and S. Lucak (2010). “Use of probiotics in gastrointestinal disorders: what to recommend?” Therapeutic advances in gastroenterology 3(5): 307-319. https://doi.org/10.1177/1756283610375685

Yousefi, B., M. Estami, H. Sabahi, A. Sadeghnejad (2019). “Probiotics can really cure an autoimmune disease?” Gene Reports 100364. http://dx.doi.org/10.1016/j.genrep.2019.100364
Yousefi, B., M. Eslami, A. Ghasemian, P. Kokhaei, A. Salek Farrokhi and N. Darabi (2019). "Probiotics importance and their immunomodulatory properties." Journal of cellular physiology 234(6): 8008-8018. https://doi.org/10.1002/jcp.27559

Zeng, H., S. Umar, B. Rust, D. Lazarova and M. Bordonaro (2019). "Secondary bile acids and short chain fatty acids in the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer." International journal of molecular sciences 20(5): 1214. https://doi.org/10.3390/ijms20051214

Zeng, J., C.-T. Wang, F.-S. Zhang, F. Qi, S.-F. Wang, S. Ma, T.-J. Wu, H. Tian, Z.-T. Tian and S.-L. Zhang (2016). "Effect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial." Intensive care medicine 42(6): 1018-1028. https://doi.org/10.1007/s00134-016-4303-x

Zhang, D., S. Li, N. Wang, H.-Y. Tan, Z. Zhang and Y. Feng (2020). "The cross-talk between gut microbiota and lungs in common lung diseases." Frontiers in Microbiology 11. https://doi.org/10.3389/fmicb.2020.00301

Zhang, T., Y. Yang, Y. Liang, X. Jiao and C. Zhao (2018). "Beneficial effect of intestinal fermentation of natural polysaccharides." Nutrients 10(8): 1055. https://dx.doi.org/10.3390/nu10081055

Zhu, N., D. Zhang and W. Wang "China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019 [published January 24, 2020]." New Engl J Med. https://dx.doi.org/10.1056/NEJMoa2001017